Immunotherapy with transfer factor of recurrent herpes simplex type I.
Arch Med Res 1995;26 Spec No:S87-92 (ISSN: 0188-4409) .... This
clinical trial of Transfer Factor, an immunomodulator, in the treatment
of herpes simplex type I, proved this agent to be more effective as
regards duration of acute phase recurrences as well as the frequency of
the reappearance of relapses of this disease. The evaluation was made
in 20 patients whose disease had been treated before with other
therapeutic agents (including acyclovir) which permitted them to be
their own controls for the comparative data obtained and submitted to
statistical analysis of the two parameters mentioned, duration of the
acute phase and frequency of relapses. Patients with compromised
cellular immunity or with any additional disease were excluded from the
study. Transfer factor, one unit, was administered subcutaneously daily
for 3 to 4 days during the acute phase of the disease, and subsequently
at 15-day intervals for the first 6 months; followed by a continuation
of monthly injections until the termination of the study period. In six
of the 20 patients there was a recurrence of the disease while
receiving maintenance dosages of TF. These patients were again given
the full initial dosage schedule and reinstated again with the
maintenance dosage. In the initial eight patients, an immune status
profile was obtained, and all results were found to be in the normal
range. This was considered sufficient evidence that the criteria for
the selection of patients excluded any with detectable variations in
the profile of the immune status, and it was decided to eliminate this
as a prerequisite for participating in the study. The results showed an
important improvement in the response to transfer factor immune
modulation therapy. A statistically significant reduction in the
frequency of recurrences within a one month period, the Student t test
gave a p = 0.0001 in TF treated patients. The average duration in days
of the acute phase also showed an important difference in favor of the
TF treatment. The U Mann-Whitney test gave a p = 0.0005. These results
suggest that, at present, TF may be considered the therapeutic agent of
choice in the treatment of herpes simplex type 1 disease.

More info at www.healthandhabitat.com